Advances in Therapy

, Volume 27, Issue 4, pp 233–244 | Cite as

Impact of change in high-density lipoprotein cholesterol from baseline on risk for major cardiovascular events

Open Access
Original Research



Low concentration of high-density lipoprotein cholesterol (HDL-C) has increasingly been recognized as a strong and independent predictor of cardiovascular risk. The aim of this study was to determine the association between change in HDL-C concentration from baseline and risk of a major cardiovascular event in a commercially insured population cohort with suboptimal HDL-C and low-density lipoprotein cholesterol (LDL-C) concentrations at baseline.


A retrospective longitudinal survival analysis was conducted using claims data from a large, commercial US health plan. To be included, patients had to be ≥50 years of age on the index date (laboratory test date between January 1, 2000 and December 31, 2003 on which both their LDL-C and HDL-C were not at goal), be continuously enrolled for a minimum of 6 months prior to and 12 months after the index date, and had to have at least one other laboratory panel result within 1 year prior to the cardiovascular event or study disenrollment. Cox proportional hazards analysis was conducted to assess the association between change in HDL-C concentrations and risk of a major cardiovascular event (defined as a ≥1-day hospitalization for a cardiovascular disease [CVD] diagnosis or an invasive cardiovascular procedure) within 5 years of the index date, after adjusting for covariates.


A 0.026 mmol/L (1 mg/dL) increase in HDL-C from baseline was associated with a statistically significant 1.9% decreased risk of a major cardiovascular event (P<0.0001; hazard ratio: 0.981; 95% CI: 0.974, 0.989), after adjustment for covariates.


Our finding of an inverse association between change in HDL-C concentrations and risk of a major cardiovascular event confirms previously reported results. Increasing HDL-C concentrations may serve as an effective measure for preventing future cardiovascular events.


cardiovascular diseases cholesterol coronary heart disease HDL LDL 


  1. 1.
    Davidson M, Meyer PM, Haffner S, et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intimamedia thickness progression in patients with type 2 diabetes mellitus. Circulation. 2008;117:2123–2130.CrossRefPubMedGoogle Scholar
  2. 2.
    Ferns G, Keti V. HDL-cholesterol modulation and its impact on the management of cardiovascular risk. Ann Clin Biochem. 2008;45:122–128.CrossRefPubMedGoogle Scholar
  3. 3.
    Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J. 2008;84:590–598.PubMedGoogle Scholar
  4. 4.
    Kim SM, Han JH, Park HS. Prevalence of low HDL-cholesterol levels and associated factors among Koreans. Circ J. 2006;70:820–826.CrossRefPubMedGoogle Scholar
  5. 5.
    Agoşton-Coldea L, Zdrenghea D, Pop D, Craăiun A, Rusu ML, Mocan T. Prevalence and particularities of dyslipidaemia in subjects with coronary heart disease. Rom J Intern Med. 2007;45:341–347.PubMedGoogle Scholar
  6. 6.
    Zhang B, Menzin J, Friedman M, Korn JR, Burge RT. Predicted coronary risk for adults with coronary heart disease and low HDL-C: an analysis from the US National Health and Nutrition Examination. Curr Med Res Opin. 2008;24:2711–2717.CrossRefPubMedGoogle Scholar
  7. 7.
    Cui Y, Watson DJ, Girman CJ, et al. Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). Am J Cardiol. 2009;104:829–834.CrossRefPubMedGoogle Scholar
  8. 8.
    Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357:1301–1310.CrossRefPubMedGoogle Scholar
  9. 9.
    Ghazzal ZB, Dhawan SS, Sheikh A, et al. Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions. Am J Cardiol. 2009;103:902–906.CrossRefPubMedGoogle Scholar
  10. 10.
    Belsey J, de Lusignan S, van Vlymen J, Chan T, Hague N. Reducing coronary risk by raising HDL-cholesterol: risk modelling the addition of nicotinic acid to existing therapy. Curr Med Res Opin. 2008;24:2703–2709.CrossRefPubMedGoogle Scholar
  11. 11.
    Bruckert E, Hansel B. HDL-C is a powerful lipid predictor of cardiovascular diseases. Int J Clin Pract. 2007;61:1905–1913.CrossRefPubMedGoogle Scholar
  12. 12.
    Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol. 2005;96:50K–58K.CrossRefPubMedGoogle Scholar
  13. 13.
    Lozano JV, Pallarés V, Cea-Calvo L, et al. Investigators of the PREV-ICTUS Study. Serum lipid profiles and their relationship to cardiovascular disease in the elderly: the PREV-ICTUS study. Curr Med Res Opin. 2008;24:659–670.CrossRefPubMedGoogle Scholar
  14. 14.
    Koro CE, Bowlin SJ, Stump TE, Sprecher DL, Tierney WM. The independent correlation between high-density lipoprotein cholesterol and subsequent major adverse coronary events. Am Heart J. 2006;151:755.e1–755.e6.CrossRefGoogle Scholar
  15. 15.
    Wei L, Murphy MJ, Macdonald TM. Impact on cardiovascular events of increasing high density lipoprotein cholesterol with and without lipid lowering drugs. Heart. 2006;92:746–751.CrossRefPubMedGoogle Scholar
  16. 16.
    Alsheikh-Ali AA, Kuvin JT, Karas RH. High-density lipoprotein cholesterol in the cardiovascular equation: does the “good” still count? Atherosclerosis. 2005;180:217–223.CrossRefPubMedGoogle Scholar
  17. 17.
    Boden WE. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol. 2000;86:19L–22L.CrossRefPubMedGoogle Scholar
  18. 18.
    Toth PP. Should we target HDL cholesterol level in lowering cardiovascular risk? Pol Arch Med Wewn. 2009;119:667–672.PubMedGoogle Scholar
  19. 19.
    Alwaili K, Awan Z, Alshahrani A, Genest J. High-density lipoproteins and cardiovascular disease: 2010 update. Expert Rev Cardiovasc Ther. 2010;8:413–423.CrossRefPubMedGoogle Scholar
  20. 20.
    Lin Y, Mousa SS, Elshourbagy N, Mousa SA. Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy. Vasc Health Risk Manag. 2010;6:73–85.PubMedGoogle Scholar
  21. 21.
    Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. Am Coll Cardiol. 2010;55:1283–1299.CrossRefGoogle Scholar
  22. 22.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a predictive factor against coronary heart disease: the Framingham study. Am J Med. 1977;62:707–714.CrossRefPubMedGoogle Scholar
  23. 23.
    Cziraky MJ, Watson KE, Talbert RL. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm. 2008;14:S3–S28.PubMedGoogle Scholar
  24. 24.
    Grover SA, Kaouache M, Joseph L, Barter P, Davignon J. Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. Arch Intern Med. 2009;169:1775–1780.CrossRefPubMedGoogle Scholar
  25. 25.
    Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16:404–423.CrossRefPubMedGoogle Scholar
  26. 26.
    Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79:8–15.PubMedGoogle Scholar
  27. 27.
    Wierzbicki AS. Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention? Curr Med Res Opin. 2005;21:299–306.CrossRefPubMedGoogle Scholar
  28. 28.
    Alagona P. Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care. 2009;15:S65–S73.PubMedGoogle Scholar
  29. 29.
    Toth PP, Zarotsky V, Sullivan JM, Laitinen D. Niacin and fibrate use among patients with high triglycerides and low high-density lipoprotein cholesterol. Curr Med Res Opin. 2009;25:1355–1363.CrossRefPubMedGoogle Scholar
  30. 30.
    McKenney JM, Jones PH, Bays HE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007;192:432–437.CrossRefPubMedGoogle Scholar
  31. 31.
    Schachter M. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Cardiovasc Drugs Ther. 2005;19:415–422.CrossRefPubMedGoogle Scholar
  32. 32.
    Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham study. Am J Cardiol. 1976;38:46–51.CrossRefPubMedGoogle Scholar
  33. 33.
    Fornasini M, Brotons C, Sellarès J, et al. Consequences of using different methods to assess cardiovascular risk in primary care. Fam Pract. 2006;23:28–33.CrossRefPubMedGoogle Scholar
  34. 34.
    Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987–1003.CrossRefPubMedGoogle Scholar
  35. 35.
    Assmann G, Schulte H, Cullen P, Seedorf U. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Münster (PROCAM) study. Eur J Clin Invest. 2007;37:925–932.CrossRefPubMedGoogle Scholar
  36. 36.
    Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ. 2008;336:1475–1482.CrossRefPubMedGoogle Scholar
  37. 37.
    Collins GS, Altman DG. An independent external validation and evaluation of QRISK cardiovascular risk prediction: a prospective open cohort study. BMJ. 2009;339:b2584.CrossRefPubMedGoogle Scholar
  38. 38.
    Wilson S, Johnston A, Robson J, et al. Predicting coronary risk in the general population-is it necessary to measure high-density lipoprotein cholesterol? J Cardiovasc Risk. 2003;10:137–141.CrossRefPubMedGoogle Scholar
  39. 39.
    Simmons RK, Coleman RL, Price HC, et al. Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care. 2009;32:708–713.CrossRefPubMedGoogle Scholar
  40. 40.
    Davis WA, Knuiman MW, Davis TM. An Australian cardiovascular risk equation for type 2 diabetes: The Fremantle Diabetes Study. Intern Med J. 2009;Mar 23. Epub ahead of print.Google Scholar
  41. 41.
    Davis WA, Colagiuri S, Davis TM. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust. 2009;190:180–184.PubMedGoogle Scholar
  42. 42.
    Vrentzos GE, Papadakis JA, Ganotakis ES, et al. Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. Int J Clin Pract. 2007;61:1643–1653.CrossRefPubMedGoogle Scholar
  43. 43.
    Knobel H, Jericó C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDS. 2007;21:452–457.CrossRefPubMedGoogle Scholar
  44. 44.
    Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis. 2005;181:93–100.CrossRefPubMedGoogle Scholar
  45. 45.
    Menown IB, Murtagh G, Maher V, Cooney MT, Graham IM, Tomkin G. Dyslipidemia therapy update: the importance of full lipid profile assessment. Adv Ther. 2009;26:711–718.CrossRefPubMedGoogle Scholar
  46. 46.
    Health Insurance Portability and Accountability Act of 1996. Public Law 104-191, 104th Congress. Available at: Accessed February 12, 2010.Google Scholar
  47. 47.
    Nichols GA, Koro CE, Chan W, et al. The association between fibrate use, change in highdensity lipoprotein cholesterol, and the risk of cardiovascular disease: a retrospective chart review involving up to 8 years of follow-up. Clin Ther. 2006;28:243–250.CrossRefPubMedGoogle Scholar
  48. 48.
    Laforest L, Souchet T, Moulin P, et al. Prevalence of low high-density lipoprotein cholesterol and hypertriglyceridaemia in patients treated with hypolipidaemic drugs. Arch Cardiovasc Dis. 2009;102:43–50.CrossRefPubMedGoogle Scholar
  49. 49.
    Cardenas GA, Lavie CJ, Cardenas V, Milani RV, McCullough PA. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management. Rev Cardiovasc Med. 2008;9:239–258.PubMedGoogle Scholar
  50. 50.
    Hobson K. Weight-loss surgery to treat diabetes. U.S. News & World Report Posted February 21, 2008. Available at: Accessed February 12, 2010.Google Scholar
  51. 51.
    Levy P. The current unmet need in type 2 diabetes mellitus: addressing glycemia and cardiovascular disease. Postgrad Med. 2009;121:7–12.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  1. 1.Global Health Economics & Outcomes ResearchAbbott LaboratoriesAbbott ParkUSA

Personalised recommendations